TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04735653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Glaucoma Coaching
Description: This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard care
Description: Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
Study: NCT05178888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4 and 6 inhibitor
Study: NCT04878601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based ART
Description: Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
Study: NCT05178888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4 and 6 inhibitor
Study: NCT04746963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.1 mg
Description: Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
Study: NCT04878601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facility-Based ART
Description: Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
Study: NCT06163196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupressure
Description: Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
Study: NCT05546359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard of care treatment
Study: NCT05853588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Description: On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
Study: NCT06121726

Intervention type: OTHER
Intervention: Ilioinguinal-Iliohypogastric nerve block
Description: local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist

Intervention type: DRUG
Intervention: Local anesthetic
Description: Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
Study: NCT05197465

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
Study: NCT04902391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Services
Description: The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
Study: NCT06013267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chin tuck against resistance exercise
Description: The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
Study: NCT03773003

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus
Study: NCT05248555

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Testing
Description: Participants will be offered finger-stick point-of-care testing for HCV
Study: NCT03773003

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking to verum, containing corn starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically looking to verum, containing corn starch.
Study: NCT05364710

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transfer factor from colostrum ultrafiltrate
Description: Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transfer factor from colostrum ultrafiltrate
Description: Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
Study: NCT05996393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: 3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: 3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: 60 mg/d orally, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: 60 mg/d orally, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
Study: NCT05871580

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency laser activated photobiomodulation
Description: Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency laser photobiomodulation inactive
Description: The same protocol as the activated group
Study: NCT05988918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: 160 mg, PO, Once daily 5 days on and 2 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: 160 mg, PO, Once daily 5 days on and 2 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: 160 mg, PO, Once daily 5 days on and 2 days off
Study: NCT04303975

Intervention type: OTHER
Intervention: clinical measurements
Description: Only clinical parameters were recorded, no intervention was made.

Intervention type: OTHER
Intervention: clinical measurements
Description: Only clinical parameters were recorded, no intervention was made.
Study: NCT06332586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diversified teaching
Description: Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
Study: NCT04853914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: HIFU treatment of Benign Prostatic Hyperplasia
Study: NCT06295900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 1 Group
Description: 20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intervention 2 Group
Description: It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Group
Description: It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
Study: NCT05989724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration
Study: NCT05925673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Stimulation (NMES)
Description: Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy + NMES
Description: Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
Study: NCT04746963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.25 mg
Description: Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.5 mg
Description: Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
Study: NCT06251570

Intervention type: OTHER
Intervention: Evaluation of Dual Task Performance
Description: The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill.

Intervention type: OTHER
Intervention: Evaluation of Dual Task Performance
Description: The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill.
Study: NCT05312606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aftoral Oral gel
Description: Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unidea Chlorhexidine digluconate mouthwash 0.20%
Description: Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
Study: NCT04784910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 20mg
Description: DWP14012 20mg, tablet, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 20mg placebo
Description: DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg placebo
Description: Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
Study: NCT05770921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter
Description: All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
Study: NCT06521723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily acute intermittent hypoxia
Description: Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking + tSTIM
Description: Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Walking + tSTIM
Description: Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
Study: NCT05399849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Exercises and Meditations
Description: Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
Study: NCT06147713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile foot device (Smart shoe)
Description: A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
Study: NCT05723458

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cream
Description: A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream containing vaseline
Study: NCT04381299

Intervention type: OTHER
Intervention: autologous platelet rich plasma
Description: The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.

Intervention type: OTHER
Intervention: saline solution
Description: The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
Study: NCT06718998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
Study: NCT06715098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoboGait
Description: RoboGait: robotic-assisted gait training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehaWalk
Description: RehaWalk: body weight-supported treadmill training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional: conventional walking training
Study: NCT05246202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-Anxiety Personalized Feedback Intervention 2.0
Description: AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Personalized Feedback Intervention
Description: C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
Study: NCT04088968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.